Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 30,000 shares of Akero Therapeutics stock in a transaction on Monday, February 10th. The stock was sold at an average price of $52.73, for a total transaction of $1,581,900.00. Following the sale, the chief executive officer now owns 686,062 shares in the company, valued at $36,176,049.26. This represents a 4.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Andrew Cheng also recently made the following trade(s):

• On Monday, January 27th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.90, for a total transaction of $1,647,000.00.
• On Tuesday, December 10th, Andrew Cheng sold 7,855 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total value of $241,855.45.
• On Monday, December 2nd, Andrew Cheng sold 25,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.09, for a total transaction of $802,250.00.

Akero Therapeutics Trading Up 2.6 %

NASDAQ:AKRO traded up $1.29 during mid-day trading on Friday, hitting $50.52. The company had a trading volume of 875,286 shares, compared to its average volume of 2,119,158. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The firm has a market cap of $3.53 billion, a P/E ratio of -13.47 and a beta of -0.11. The business's fifty day moving average is $34.96 and its two-hundred day moving average is $30.82.

Institutional Trading of Akero Therapeutics

Hedge funds have recently modified their holdings of the company. Sterling Capital Management LLC increased its stake in Akero Therapeutics by 764.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock valued at $50,000 after purchasing an additional 1,582 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company's stock valued at $71,000 after buying an additional 446 shares during the period. Quarry LP bought a new stake in shares of Akero Therapeutics in the 4th quarter valued at $83,000. Eastern Bank acquired a new stake in Akero Therapeutics during the 3rd quarter worth $100,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in Akero Therapeutics by 6.8% during the fourth quarter. Ameritas Investment Partners Inc. now owns 7,092 shares of the company's stock worth $197,000 after acquiring an additional 450 shares in the last quarter.

Analyst Ratings Changes

AKRO has been the subject of several research analyst reports. Citigroup lifted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Bank of America upgraded shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. Morgan Stanley increased their price objective on Akero Therapeutics from $46.00 to $96.00 and gave the company an "overweight" rating in a research report on Tuesday, January 28th. UBS Group boosted their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Finally, HC Wainwright raised their price target on Akero Therapeutics from $50.00 to $72.00 and gave the company a "buy" rating in a report on Monday, January 27th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $75.86.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.